Product Information
ROFLUMILAST 500 MCG TABLET is a generic product labeled by Major Pharmaceuticals, priced at $0.3113 per EA under NDC 00904739946. Its NADAC has been published 137 times since Feb 21, 2024.
FDA first approved this application on Sep 7, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
500 ug/1
Manufacturer
Major PharmaceuticalsNDC
00904739946
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ROFLUMILASTApproval Type
Generic (ANDA)
FDA Application
ANDA208256FDA Approved
9/7/2022
TE Code
AB
On Market Since
12/26/2023
Pharmacological Classes
Price Statistics
The NADAC for ROFLUMILAST 500 MCG TABLET has been published 137 times since Feb 21, 2024, and over the history we have for it it has declined 23.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3113 per EA |
|---|---|
| All-time high | $0.4359 (Apr 10, 2024) |
| All-time low | $0.2563 (Nov 20, 2024) |
| 52-week high | $0.3445 |
| 52-week low | $0.3113 |
| Median price | $0.3232 |
| Average price | $0.3402 |
| Largest weekly change | +40.4% (Jun 19, 2024) |
| Weeks tracked | 137 |
| Tracking since | Feb 21, 2024 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Major Pharmaceuticals manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Roflumilast market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Phosphodiesterase 4 Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ROFLUMILAST 500 MCG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ROFLUMILAST 500 MCG TABLET, manufactured by Major Pharmaceuticals, is $0.3113 per EA (NDC 00904739946), effective Sep 30, 2026.
How has the price of ROFLUMILAST 500 MCG TABLET changed over time?
Over the history we have for it, the NADAC for ROFLUMILAST 500 MCG TABLET has declined 23.1%. It has been tracked across 137 weekly CMS publications since Feb 21, 2024.
What are the highest and lowest recorded NADAC prices for ROFLUMILAST 500 MCG TABLET?
Since Feb 21, 2024, the NADAC for ROFLUMILAST 500 MCG TABLET has ranged from a low of $0.2563 (Nov 20, 2024) to a high of $0.4359 (Apr 10, 2024), with a median of $0.3232 per EA.
Are there cheaper alternatives to ROFLUMILAST 500 MCG TABLET?
7 manufacturers publish a NADAC-priced product with the same active ingredient and strength as ROFLUMILAST 500 MCG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures ROFLUMILAST 500 MCG TABLET?
ROFLUMILAST 500 MCG TABLET (NDC 00904739946) is labeled by Major Pharmaceuticals, and CMS classifies it as a generic product.